drugset / Trial / NCT04042805
Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This ia a single-arm, single-center, not-randomized, open-label phase II study. The purpose of this study is to evaluate the efficacy and safety of Sintilimab (PD-1 antibody) combined with Lenvatinib(TKI) for the treatment of local advanced hepatocellular carcinoma.
Timeline
- Start
- 2019-08-01
- Primary completion
- 2022-08-30
- Completion
- 2024-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |